« Go Back

Pipeline Therapeutics to Present at Multiple Investor Conferences in May 2022

SAN DIEGO, May 5, 2022 – Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that company management will present at the following investor conferences:

  • 2022 RBC Capital Markets Global Healthcare Conference
    • Wednesday, May 18, 2022 at 8:00 am ET
  • UBS Global Healthcare Conference
    • Wednesday, May 25, 2022 at 8:30 AM ET

About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair.  The Company has a broad pipeline of programs to address CNS and neuro-otology conditions. Its flagship program, PIPE-307, has completed a Phase 1 clinical trial in healthy volunteers and has received IND clearance from the FDA to initiate a Phase 1b/2a trial in relapsing-remitting MS patients.  For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com

Investor Contact:
Amy Conrad
858-914-1962
amy@juniper-point.com